Zoetis Inc. $ZTS Position Lowered by Keybank National Association OH

Keybank National Association OH decreased its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 34.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,908 shares of the company’s stock after selling 23,783 shares during the quarter. Keybank National Association OH’s holdings in Zoetis were worth $3,136,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Cassaday & Co Wealth Management LLC bought a new stake in shares of Zoetis during the first quarter worth about $28,000. Wellington Grp LLC boosted its position in Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after buying an additional 267 shares during the period. University of Texas Texas AM Investment Management Co. bought a new stake in Zoetis during the 2nd quarter worth approximately $25,000. Dunhill Financial LLC grew its holdings in Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares during the last quarter. Finally, Dakota Community Bank & Trust NA grew its holdings in Zoetis by 112.4% during the 1st quarter. Dakota Community Bank & Trust NA now owns 393 shares of the company’s stock worth $46,000 after acquiring an additional 208 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 0.2%

Shares of ZTS stock opened at $83.65 on Monday. The company has a market cap of $33.99 billion, a P/E ratio of 14.23, a PEG ratio of 1.21 and a beta of 0.67. The stock has a 50 day simple moving average of $76.28 and a two-hundred day simple moving average of $91.56. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35. Zoetis Inc. has a fifty-two week low of $68.77 and a fifty-two week high of $132.49.

Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.24. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The company’s revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.70 earnings per share. Research analysts forecast that Zoetis Inc. will post 6.29 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be paid a $0.53 dividend. The ex-dividend date is Friday, October 30th. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. Zoetis’s payout ratio is currently 36.05%.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. The Goldman Sachs Group began coverage on shares of Zoetis in a research report on Friday, October 16th. They issued a “neutral” rating and a $74.00 price target for the company. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research note on Tuesday, August 25th. UBS Group lifted their target price on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 27th. BNP Paribas Exane dropped their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Finally, Morgan Stanley cut their price target on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a research report on Thursday, October 29th. Eight research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $101.25.

View Our Latest Stock Analysis on Zoetis

Zoetis Company Profile

(Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.